Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSD-103
- Development stage
- Unknown
- Lead developer
- Mindstate Design Labs
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MSD-103 is a clinical-stage, small molecule fixed-dose combination of a primer and a probe being developed by Mindstate Design Labs. It is designed to selectively target and produce a 'warmth' psychoactive effect profile. The candidate is being evaluated in a Phase 1b/2a clinical trial (referred to as the WARMTH arm) as part of Mindstate's pipeline of customized psychoactive states of consciousness.
- Other names
- WARMTH arm
Beyond the preview
Go deeper on MSD-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSD-103.